15-deoxy-Δ12,14-prostaglandin J2 inhibits angiotensin ii-induced fibronectin expression via hepatocyte growth factor induction in human peritoneal mesothelial cells

Therapeutic Apheresis and Dialysis

Volumn 14, Issue 1, 2010, Pages 43-51

  Yokoyama, Yukio ^a   Masaki, Takao ^a   Kiribayashi, Kei ^a   Nakashima, Ayumu ^a   Kokoroishi, Keiko ^a   Ogawa, Takahiko ^b   Kohno, Nobuoki ^a   Yorioka, Noriaki ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b HIROSHIMA PREFECTURAL HOSPITAL   (Japan)

Author keywords

Angiotensin; Hepatocyte growth factor; Mesothelial cell; Peritoneal fibrosis; Peroxisome; Proliferator activated receptor

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; 2 CHLORO 5 NITROBENZANILIDE; 5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; ANGIOTENSIN II; FIBRONECTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; 15 DEOXY DELTA(12,14) PROSTAGLANDIN J2; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J2; DRUG DERIVATIVE; IMMUNOLOGIC FACTOR; PROSTAGLANDIN D2;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; HUMAN CELL; MESOTHELIUM CELL; PERITONEUM CELL; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING; ANALYSIS OF VARIANCE; CELL CULTURE; DRUG ANTAGONISM; EPITHELIUM; METABOLISM; PERITONEUM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANALYSIS OF VARIANCE; ANGIOTENSIN II; BLOTTING, WESTERN; CELLS, CULTURED; EPITHELIUM; FIBRONECTINS; HEPATOCYTE GROWTH FACTOR; HUMANS; IMMUNOLOGIC FACTORS; PERITONEUM; PROSTAGLANDIN D2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; UP-REGULATION;

EID: 77149179358     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2009.00702.x     Document Type: Article

References (25)

1. Williams JD, Craig KJ, Topley N et al. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002 13 : 470 479.
2. Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM. mPPARγ2; tissue-specific regulator of an adipocyte enhancer. Genes Dev 1994 8 : 1224 1234.
3. 2 is a ligand for the adipocyte determination factor PPARγ. Cell 1995 83 : 803 812.
4. Li Y, Wen X, Spataro BC, Hu K, Dai C, Liu Y. Hepatocyte growth factor is a downstream effector that mediates the antifibrotic action of peroxisome proliferator-activated receptor-γ agonists. J Am Soc Nephrol 2006 17 : 54 65.
5. Guo B, Koya D, Isono M, Sugimoto T, Kashiwagi A, Haneda M. Peroxisome proliferator-activated receptor-γ ligands inhibit TGF-β1-induced fibronectin expression in glomerular mesangial cells. Diabetes 2004 53 : 200 208.
6. Asakawa M, Takano H, Nagai T et al. Peroxisome proliferator-activated receptor γ plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. Circulation 2002 12 : 1240 1246.
7. Sakamoto N, Sugimura K, Kawashima H et al. Influence of glucose and inflammatory cytokines on TGF-β1 and CTGF mRNA expressions in human peritoneal mesothelial cells. Int J Mol Med 2005 15 : 907 911.
8. Yung S, Chan TM. Peritoneal mesothelial cells and the extracellular matrix. Nephrology 2001 6 : 250 258.
9. Kiribayashi K, Masaki T, Naito T et al. Angiotensin II induces fibronectin expression in human peritoneal mesothelial cells via ERK1/2 and p38 MAPK. Kidney Int 2005 67 : 1126 1135.
10. Nakamura T, Nishizawa T, Hagiya M et al. Molecular cloning and expression of human hepatocyte growth factor. Nature 1989 342 : 440 443.
11. Naiki Y, Matsuo K, Matsuoka T, Maeda Y. Possible role of hepatocyte growth factor in regeneration of human peritoneal mesothelial cells. Int J Artif Organs 2005 28 : 141 149.
12. Matsuo K, Maeda Y, Naiki Y et al. Possible effects of hepatocyte growth factor for the prevention of peritoneal fibrosis. Nephron Exp Nephrol 2005 99 : e87 94.
13. Jiang JG, Johnson C, Zarnegar R. Peroxisome proliferator-activated receptor γ-mediated transcriptional up-regulation of the hepatocyte growth factor gene promoter via a novel composite cis-acting element. J Biol Chem 2001 276 : 25049 25056.
14. Doi S, Masaki T, Arakawa T et al. Protective effects of peroxisome proliferator-activated receptor gamma ligand on apoptosis and hepatocyte growth factor induction in renal ischemia-reperfusion injury. Transplantation 2007 84 : 207 213.
15. Smolen GA, Sordella R, Muir B et al. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci USA 2006 103 : 2316 2321.
16. Taher TE, Tjin EP, Beuling EA, Borst J, Spaargaren M, Pals ST. c-Cbl is involved in Met signaling in B cells and mediates hepatocyte growth factor-induced receptor ubiquitination. J Immunol 2002 169 : 3793 3800.
17. Mezzano SA, Ruiz-Ortega M, Egido J. Angiotensin II and renal fibrosis. Hypertension 2001 38 : 635 638.
18. Noh H, Ha H, Yu MR, Kim YO, Kim JH, Lee HB. Angiotensin II mediates high glucose-induced TGF-β1 and fibronectin upregulation in HPMC through reactive oxygen species. Perit Dial Int 2005 25 : 38 47.
19. Bozkurt D, Taskin H, Sezak M et al. Rosiglitazone, a peroxisome proliferator-activated receptor agonist, improves peritoneal alterations resulting from an encapsulated peritoneal sclerosis model. Adv Perit Dial 2008 24 : 32 8.
20. Leclercq IA, Sempoux C, Stärkel P, Horsmans Y. Limited therapeutic efficacy of pioglitazone on progression of hepatic fibrosis in rats. Gut 2006 55 : 1020 1029.
21. Burgess HA, Daugherty LE, Thatcher TH et al. PPARγ agonists inhibit TGF-β induced pulmonary myofibroblast differentiation and collagen production: implications for therapy of lung fibrosis. Am J Physiol Lung Cell Mol Physiol 2005 288 : L1146 53.
22. Dai C, Yang J, Bastacky S, Xia J, Li Y, Liu Y. Intravenous administration of hepatocyte growth factor gene ameliorates diabetic nephropathy in mice. J Am Soc Nephrol 2004 15 : 2637 2647.
23. Nakamura S, Tachikawa T, Tobita K et al. Role of advanced glycation end products and growth factors in peritoneal dysfunction in CAPD patients. Am J Kidney Dis 2003 41 (Suppl. 1 S61 7.
24. Nakamura S, Niwa T. Pyridoxal phosphate and hepatocyte growth factor prevent dialysate-induced peritoneal damage. J Am Soc Nephrol 2005 16 : 144 150.
25. Yang J, Dai C, Liu Y. Hepatocyte growth factor suppresses renal interstitial myofibroblast activation and intercepts smad signal transduction. Am J Pathol 2003 163 : 621 632.